Monash IVF reveals second embryo mix-up after admitting to major accident just months earlier
Monash IVF has mistakenly transferred the wrong embryo into a patient in the second major incident for the company in about two months.
On June 5 the Clayton fertility clinic, in Melbourne's south-east, accidentally put a patient's own embryo into a patient rather than an embryo from their partner as planned.
"Monash IVF has extended its sincere apologies to the affected couple, and we continue to support them," the company said in a statement on the ASX on Tuesday.
The company said it is conducting an internal investigation into the incident as it comes just months after it admitted one of its patients had given birth to a stranger's child in a shocking embryo mix-up that made headlines across the country.
"Commencing immediately, Monash IVF will implement interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes," Monash IVF said.
"Whilst industry leading electronic witness systems have and are being rolled out across Monash IVF, there remains instances and circumstances whereby manual witnessing is required.
"Monash IVF has disclosed the incident to the relevant assisted reproductive technology (ART) regulators, namely the Reproductive Technology Accreditation Committee certifying body and Victorian Health Regulator."
The company's share price has sunk more than 21 per cent, down to 59 cents, on Tuesday morning after revealing the news.
More to come.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
29 minutes ago
- News.com.au
German investor Deutsche Balaton has built an ASX empire, and it's backing this battery stock to the hilt
German investor Deutsche Balaton has built an empire of ASX resources stocks It's also branching out, holding a role as battery stock Altech's major shareholder This is how DB's Wilhelm Zours invests, and why Altech is one of its key ASX holdings Any clued-in observer of the energy market knows solar and wind power is just one part of the solution for green energy. Now mainstream technologies, the key is not solar panels and turbines, it's working out how to store that energy for round-the-clock power. With the growth in the rollout and usage of AI, experts expect to see a rise in the use of battery energy storage systems (BESS), allowing data centres to be supplied with a cost effective and steady base-load. While the battery market explores everything from lead-acid to sodium-ion, Altech Batteries (ASX:ATC) stands alone on the ASX with a game-changing chemistry using simple table salt and nickel powder – sidestepping costly, high-demand critical minerals. And the company's technology comes with a key backer in one of the ASX's leading resources investors, a major show of support from a backer normally known for providing the capital to turn lithium and gold small caps into major players. Founded and led by German businessman Wilhelm Konrad Zours, Deutsche Balaton has been a fixture in ASX resources investing for years. Its appearance at the head of Altech's register, with a combined stake across multiple entities of 16.5%, lends credence to the battery tech stock's growth story. Investor backing Deutsche Balaton's backing has gone further than simply holding equity. In a strong vote of confidence, the German investment firm agreed to a $4.28M loan facility in March to fuel Altech's CERENERGY and Silumina Anodes developments. By offering the loan in the form of a binding bond note subscription deed, Altech has been able to draw down the funds in the form of bearer bonds, with interest set at 7% per annum. Speaking with Stockhead, Altech chief financial officer Martin Stein said Deutsche Balaton has been a supportive shareholder throughout the years, first joining the company's register about six years ago. The synergies are even stronger than many of the firm's ASX investments, given Altech's plans to base its plants in an industrial park in Saxony, close to the European EV industry. 'Deutsche Balaton has provided capital and debt instruments to help finance Altech's objectives,' he said. 'From a geographical standpoint, being close to both of Altech's battery projects in Germany, I think the company can see the enormous potential of CERENERGY and the Silumina Anodes projects.' How does Altech's tech work? Without the danger of thermal runaway, extended durability and a broad operating range from -40°C to 60°C, Altech's solid-state chemistry dubbed CERENERGY sets a new standard for battery safety and performance in stationary storage solutions like grid infrastructure and data centres. Altech's other development, Silumina Anodes, is tackling one of the toughest battery challenges when using silicon in battery anodes, the issue of silicon swelling. During charging, silicon particles can expand by as much as 300%, causing swelling and fracturing that may lead to battery failure. It also tends to immobilise lithium ions, which can reduce overall performance and shorten battery lifespan. By using alumina-coated particles, Altech believes it has cracked the silicon code. Through in house R&D and by optimising the silicon content to 5%, the company has achieved a 50% higher energy battery with improved cyclability and battery life. In its push to bring patented technology to market, Altech has built a pilot plant next to the proposed project site in Saxony, Germany, where it is now successfully producing coated silicon for its Silumina Anodes product qualification. Broad ASX exposure Altech may have drawn Deutsche Balaton to its battery-tech plans, but the firm is active across a broader portfolio of ASX resources companies. Among its best bets was backing Azure Minerals, which netted the connected Delphi Group a $176m payout after the Andover lithium project owner's $1.7bn sale to SQM and Hancock Prospecting. Its other big investments include a 6.32% stake in critical minerals explorer Evolution Energy Minerals (ASX:EV1), owners of the Chilalo graphite project in Tanzania which is advancing towards FID. An updated DFS for Chilalo in March 2023 demonstrated a high-quality project based on average annual throughput of 500,000tpa at 10.6% TGC to produce 52,000tpa of graphite concentrate for downstream processing. The company recently unveiled a new strategic direction, focused on acquiring gold development assets in Africa, with the backing of its largest shareholder – Sustainable Resources Fund (ARCH). The German firm has also taken position in several ASX gold stocks, now reaping the rewards of a gold price near all-time highs at ~$5000/oz. Its portfolio includes 1% of Spartan Resources (ASX:SPR), having largely cashed out by selling much of its stake to SPR's now merger partner Ramelius Resources (ASX:RMS) in a strategic move last year. The gold developer had massively rerated off the back of its Never Never discovery at the Dalgaranga gold project – a reward for Zours and Co.'s patience having backed the firm back in its desperate Gascoyne Resources days. Also in WA and PNG's gold fields it holds major positions in Matsa Resources (ASX:MAT) (~19.6%), Patronus Resources (ASX:PTN) (42.35%), and Geopacific Resources (ASX:GPR) (~46%). Over in PNG, a move from St Barbara to acquire the holding of Deutsche linked PTN in GPR could open up more M&A value creation for the German money men. It's also active across other commodities like high purity alumina (HPA) with a 6.17% holding in Impact Minerals (ASX:IPT), the developers of the 80% owned Lake Hope project in WA. Lake Hope has a measured resource of 730,000t grading 25.8% alumina, or 189,000t of contained alumina, providing strong assurance that it can support the proposed 10,000tpa HPA plant over a 15-year period. This resource will also underpin a maiden probable or proven reserve subject to ongoing mining studies, test work and economic studies to be completed as part of the PFS currently underway. Deutsche Balaton holds a 21.7% stake in Tivan (ASX:TVN), giving it exposure to vanadium and fluorite, along with copper-zinc through a 2.3% stake in Orion Minerals (ASX:ORN).
News.com.au
29 minutes ago
- News.com.au
Ten Bagger: Platinum is showing green shoots – is it time to get in early?
Welcome to Ten-Bagger, where Lowell Resources Fund chief investment officer John Forwood gives us his take on a sector of the ASX resources market full of value. This month, John looks at the turnaround in platinum and palladium prices. Running at massive deficits hasn't been enough to keep platinum and palladium prices from scraping along deep into the cost curve over the past two years, a massive reversal of fortune from the early days of Russia's invasion of Ukraine, when concerns about Russia's control of the palladium market sent prices soaring. But a number of analysts and fund managers have kept tabs on the commodities known as platinum group metals – principally platinum, palladium and rhodium – in recent months. With prices well below the cost base of most miners in South Africa – the world's top producer by a wide margin – it's seemed logical that something would have to give. The metals have dual uses. They are, like gold and silver, precious metals purchased for investments and crafted into jewellery. But their key demand driver is from the catalytic converters that reduce emissions from internal combustion engine and hybrid motor vehicles. Carmakers have been able to rely on stockpiles as prices have tumbled. But supply-demand metrics are turning increasingly in favour of miners. The World Platinum Investment Council said in May that supply this year will fall 4% to ~7Moz, delivering a platinum deficit of 966,000oz, a number that's expanded by 115,000oz from forecasts just three months. Supply will drop to a five-year low, leading to a third straight year of deficits. Now, the worm could well be turning for the price. "The platinum price has jumped up by around at least 15% in the last month or so," Lowell Resources Fund (ASX:LRT) CIO John Forwood said. "It's gone from the mid-900 US dollars an ounce mark to ~US$1224/oz." Market moves Now at its highest point in four years, platinum prices have surged to a more than 30% YTD gain. Palladium has followed, up 19% to US$1087.50/oz. That's a far cry from the US$3400/oz seen post Russia's invasion. On current trends, Forwood says some reports have above ground stockpiles of platinum depleting in as little as two years. "We are seeing sort of a deceleration, if you like, in the move away from ICE vehicles," Forwood said. " 2025 has been the year of the hybrid. The demand from auto-cats for PGMs has been stronger than expected. But also, I think there's been a lot of investment demand for platinum and that's what's really pushed the price in the last month or two." Green shoots for the precious metals have investor eyes turning to the next stocks on the production front. "We're definitely seeing some good market moves in the price, and that's translated massively into Southern Palladium's share price, which got down to around some 20 cents, and now it's at 50 odd cents," Forwood told Stockhead. Southern Palladium (ASX:SPD) listed in 2022 to raise capital for its Bengwenyama mine in South Africa, one of a handful of undeveloped platinum reef operations in South Africa, where it holds a 70% stake alongside local Black Economic Empowerment partners. A PFS last year posted an ore reserve of 6.29Moz at 6.17g/t 6E PGMs. It proposed a 29-year mine life delivering 400,000ozpa of PGM, with life of mine all in sustaining costs of US$800/oz, generating a 50% margin at just US$1200/oz Pt, US$1100/oz Pd and US$6200/oz Rh. SPD announced a trading halt on Tuesday to raise fresh cash, unsurprising after a 120% one-month gain. Fresh blood It's little secret the platinum sector is crying out for some fresh blood, with historic operations facing cost escalation and declining grade. Deficits are projected until the end of the WPIC's forecast period in 2029. Forwood said South Africa's mining industry, the engine room for the platinum market, was a 'sunset industry'. A historic mining Mecca, it's become increasingly difficult to operate there as public infrastructure fails. A number of producers in the PGM industry are lossmaking, but are only motivated to stay open by their social licence and government pressure. "A number the PGM shafts on the Bushveld in South Africa are actually well and truly uneconomic at the moment and arguably being kept open for non-economic reasons to maintain employment," Forwood said. "So at some point, unless there's a dramatic shift in the price, those shafts are going to have to close or you're going to see a very big change in price and that's probably more likely because that will address the supply-demand deficit." SPD has had a large impending capital bill weighing on its share price, a potential US$452m in peak funding according to its PFS. But Forwood said it had been working on alternative solutions including funding arrangements and staged development. His other PGM pick is Talon Metals. Listed on the TSX, Talon holds the Tamarack JV in Minnesota with non other than mining giant Rio Tinto (ASX:RIO). The project hosts an indicated resource of 8.6Mt at 1.73% nickel and 0.92% copper and inferred resource of 8.5Mt at 0.83% Ni and 0.55% Cu. Assays from a revisited historic drill hole have lifted the lid on the deposit's growth potential, coming in at 34.9m grading a ludicrous 28.88% NiEq or 57.76% CuEq. That included 8.65g/t palladium, 16.31g/t platinum, 9.18g/t gold and 42.92g/t silver. Bonkers. "You wouldn't believe it, the grades are enormous. That's not just a PGM project, but the PGM grades on their own are more than economic," Forwood said. "When you add the nickel, copper, cobalt, gold, silver to it, it's just a stunning result. "Lowell's been a shareholder in that company for a number of years now. I'm very pleased to see some of these results coming back." Other PGM stocks on the ASX include Future Metals (ASX:FME), the owner of the Panton project in WA, up 90% off a low base, Julimar project owner Chalice Mining (ASX:CHN), which is up around 26% YTD, and Implats' Zimbabwean subsidiary Zimplats Holdings (ASX:ZIM), the sole operating miner on the ASX, up 22% YTD.
ABC News
an hour ago
- ABC News
Calls for federal IVF regulation and DNA testing after second Monash embryo mix-up
IVF activists are calling for an urgent meeting with the federal health minister, and are suggesting children born through assisted reproduction should be DNA tested. It comes after the latest embryo mix-up this week, involving Monash IVF. The fertility giant apologised for a second time in as many months, for incorrectly transferring the wrong embryo to a patient. The company announced to the Australian Securities Exchange (ASX) the bungle had occurred last week at its laboratory in Clayton, Melbourne, resulting in a patient receiving her own embryo "contrary to the treatment plan which designated the transfer of an embryo of the patient's partner". Two months ago, the company revealed a Brisbane patient was mistakenly implanted with another patient's embryo. That patient gave birth to a baby who had no genetic link to her in 2023, but Monash IVF only discovered the error in February this year after the birth parents asked to transfer their remaining embryos to another provider. In a letter to Mark Butler and other Australian health ministers, who will meet in Melbourne tomorrow, IVF activists Anastasia Gunn and Katherine Dawson called for federal laws to regulate the assisted reproductive technology (ART) industry and the establishment of a national central donor register. While Victoria has been governed by ART laws for more than a decade, Queensland's legislation to regulate the industry was only passed last year. The women have argued IVF mix-ups are not "rare mistakes", as industry professionals say. "These are the direct consequence of systemic failures," the women said in the letter. "While some impacted families are choosing privacy, we are stepping forward to speak out, on behalf of all the people who can't, and all those who will discover they have been harmed." In Ms Gunn's case, her three sons were conceived through donor sperm at the Queensland Fertility Group between 2006 and 2014. She and her partner paid for the same donor to be used for each child. But DNA testing now shows their eldest son is not biologically related to their two younger boys, who have both been diagnosed with health conditions. QFG has maintained its records show the same donor was used for all three children. Given the latest issues, Ms Gunn has urged all ART patients to consider DNA testing of their children. "At best, it will give them peace of mind," she told the ABC. "At worst, it will show the degree of lack of regulation and adherence to standards that these clinics have engaged in. "The clinics should be offering this DNA testing to whomever requests it. If they have nothing to hide, then they would be happy to do so." Sydney Law School lecturer and Sydney Health Law (Centre) deputy director Christopher Rudge said these IVF events and mistakes were "relatively rare" however, he shared others' concerns that it was "hard to know without specific data". Victoria's health regulator is investigating the latest Monash IVF incident. Dr Rudge said the state's regulatory authority — the Secretary for the Department of Health — has a range of powers, including being able to impose specific conditions on a provider's registration, suspend it if there are grounds to do so, or refer matters for prosecution. He said the system was "well regulated" in Victoria, adding "the real key is for those regulations to be used" and for enforcement to take place. "I note some calls for a uniform federal form of regulation or oversight, however I think if there was a federal instrument it would probably look like the Victorian one looks like already," he said. "So it's probably more a matter of the Victorian regulator taking action." In a statement, Mr Butler said he had put the regulation of the IVF sector on the agenda for the health ministers' meeting on Friday. The ABC approached Monash IVF and QFG about DNA testing. Monash IVF referred the ABC to the fertility company's ASX statement and QFG failed to answer any questions.
